Brand Reference: Nurtec ODT
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rimegepant Sulfate ODT RxNorm Concept ID | 2282909 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $118.5000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1065.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | Requires Local / Compounded Rx | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $195.00 / mo | 23 Zero-PHI Verified Patient Logs |
Directly blocks calcitonin gene-related peptide (CGRP) receptors across trigeminovascular meningeal pathways WITHOUT 5-HT1B arterial vasoconstriction or medication-overuse rebound—uniquely FDA-cleared for BOTH acute abortive relief and every-other-day preventive migraine therapy.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Rimegepant Sulfate ODT (Nurtec ODT, RxCUI 2282909) at $118.5000 per unit, whereas walk-in chain pharmacies bill cash patients an average of $1065.00 monthly—creating a 82% ($870.00/mo) wholesale arbitrage spread down to $195.00.
Systemic exposure to Rimegepant Sulfate ODT reflects 64% lyophilized ODT sublingual/lingual absorption kinetics and hepatic cyp3a4 (major) and minor cyp2c9; 78% unchanged elimination, sustaining receptor engagement across a 11 hours half-life window (45–60 minutes pain relief lasting up to 48 hours response profile).
Dosing protocols (75 mg ODT PRN acute migraine (max 1/24h) or 75 mg ODT every other day (preventive regimen)) balance efficacy (92.10% patient satisfaction across 23 logs) against mild nausea (2%) (5% of reports), indigestion (3% of reports), with strict avoidance in strong cyp3a4 inhibitors or inducers; end-stage hepatic child-pugh c failure.
Across 23 verified cash-pay logs, Rimegepant Sulfate ODT achieves a 92.10% Worth-It rating with out-of-pocket spend averaging $195.00/mo versus $1065.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to TeleMed at 75 mg ODT PRN acute migraine (max 1/24h) for Rimegepant Sulfate ODT; monthly out-of-pocket dropped to $171.60 compared with $1065.00 retail.
Completed 10 weeks on Rimegepant Sulfate ODT (75 mg ODT every other day (preventive regimen)). Zero notable side effects on steady dosing.
Consistent biomarker response on 75 mg ODT PRN acute migraine (max 1/24h) Rimegepant Sulfate ODT sourced via Cash Clinic ($226.20/mo cash pay without insurance prior authorization).